BIOCON GROUP

FACT SHEET

March - 2015

17/21

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET **(Rs. Crores)**

	March 31, 2015	March 31, 2014
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b)Reserves and surplus	3,171	2,927
	3,271	**3,027**
Minority interest	172	82
Non-current liabilities		
(a) Long-term borrowings	770	606
(b)Deferred tax liability (net)	42	45
(c)Other long-term liabilities	552	603
(d) Long-term provisions	15	8
	1,379	**1,262**
Current liabilities		
(a)Short-term borrowings	261	244
(b)Trade payables	429	347
(c)Other current liabilities	706	612
(d)Short-term provisions	157	177
	1,553	**1,380**
TOTAL	6,375	5,751
ASSETS		
Non-current assets		
(a) Fixed assets	3,280	2,719
(b) Goodwill	26	12
(c) Non-current investments	-	65
(d) Long term loans and advances	369	269
(e) Other non-current assets	137	47
(f) Deferred tax asset	-	-
	3,812	**3,112**
Current assets		
(a) Current Investments	230	700
(b) Inventories	453	377
(c)Trade receivables	771	600
(d)Cash and cash equivalents	938	804
(e)Short term loans and advances	81	82
(f)Other current assets	90	76
	2,563	**2,639**
TOTAL	6,375	5,751

18/21

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT **(Rs. Crores)**

Particulars	FY 15	FY 14	Variance
INCOME			
Biopharmaceuticals	**2,236**	**2,138**	5%
Biopharma *	1,806	1,747	3%
Branded formulations - India	430	391	10%
Contract research	**823**	**715**	15%
Total Sales	**3,059**	**2,853**	7%
Other income	84	80	4%
Total Revenue	**3,143**	**2,933**	7%
EXPENDITURE			
Material & Power costs	1,423	1,348	5%
Staff costs	493	428	15%
Research & Development **	169	131	29%
Other expenses	309	283	10%
Manufacturing, staff & other expenses	**2,394**	**2,190**	
EBITDA	**749**	**743**	1%
Interest & Finance charges	9	2	
Depreciation & Amortisation	221	203	9%
PBT BEFORE EXCEPTIONAL ITEM	**519**	**538**	-3%
Exceptional item, Net	105	-	
PBT	**624**	**538**	16%
Taxes#	96	107	
NET PROFIT BEFORE MINORITY INTEREST	**528**	**431**	23%
Minority interest	31	17	
NET PROFIT FOR THE PERIOD	**497**	**414**	20%
EPS Rs.	**24.8**	**20.7**	

Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers

** Biopharma Income includes:*		
Licensing Income	*43*	*15*
*** Gross Research & Development expenses*	*329*	*169*

Tax incidence in the hands of BRL on the sale of shares has been fully offset against business losses of BRL. BRL had created deferred tax asset of Rs 10 as at December 31, 2014 which has been utilised on consummation of sale in current quarter.

19/21

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT **(Rs. Crores)**

Particulars	Q4 FY 15	Q3 FY 15	Variance
INCOME			
Biopharmaceuticals	**592**	**541**	9%
Biopharma *	494	436	13%
Branded formulations - India	98	105	-6%
Contract research	**238**	**220**	9%
Total Sales	**830**	**761**	9%
Other income	24	18	34%
	854	779	10%
EXPENDITURE			
Material & Power costs	376	360	4%
Staff costs	126	126	0%
Research & Development **	56	47	20%
Other expenses	94	76	24%
Manufacturing, staff & other expenses	**652**	**609**	
EBITDA	202	170	19%
Interest & Finance charges	-	5	
Depreciation & Amortisation	59	56	4%
PBT BEFORE EXCEPTIONAL ITEM	143	109	32%
Exceptional item, Net	105	-	
PBT	248	109	129%
Current taxes	22	11	
Taxes on exceptional items	10		
NET PROFIT BEFORE MINORITY INTEREST	216	98	122%
Minority interest	15	7	
NET PROFIT FOR THE PERIOD	201	91	122%
EPS Rs.	**10.0**	**5.1**	

Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers

** Biopharma Income includes:*		
Licensing Income	5	10
*** Gross Research & Development expenses*	100	85

20/21

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT **(Rs. Crores)**

Particulars	Q4 FY 15	Q4 FY 14	Variance
INCOME			
Biopharmaceuticals	**592**	**535**	**11%**
Biopharma *	494	442	12%
Branded formulations - India	98	93	6%
Contract research	**238**	**188**	**27%**
Total Sales	**830**	**723**	**15%**
Other income	24	23	8%
TOTAL REVENUE	**854**	**746**	**15%**
EXPENDITURE			
Material & Power costs	376	332	13%
Staff costs	126	112	13%
Research & Development **	56	29	93%
Other expenses	94	80	17%
Manufacturing, staff & other expenses	**652**	**553**	
EBITDA	**202**	**193**	**5%**
Interest & Finance charges	-	1	
Depreciation & Amortisation	59	54	8%
PBT BEFORE EXCEPTIONAL ITEM	**143**	**138**	**4%**
Exceptional item, Net	105	-	
PBT	**248**	**138**	**80%**
Current taxes	22	19	
Taxes on exceptional items	10		
NET PROFIT BEFORE MINORITY INTEREST	**216**	**119**	**83%**
Minority interest	15	6	
NET PROFIT FOR THE PERIOD	**201**	**113**	**78%**
EPS Rs.	**10.0**	**5.7**	

Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers

** Biopharma Income includes:*		
Licensing Income	5	-
*** Gross Research & Development expenses*	100	52